AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems, today announced that it will
participate in the following investor conferences during August:
-
The BMO Capital Markets Focus on Healthcare Conference at the
Millennium Broadway Hotel in New York on Wednesday, August 5, 2009.
David J. Drachman, President and Chief Executive Officer, is scheduled
to present at 9:00 a.m. Eastern Time.
-
The Canaccord Adams Global Growth Conference at the Intercontinental
Hotel in Boston on Thursday, August 13, 2009. Mr. Drachman is
scheduled to present at 8:00 a.m. Eastern Time.
-
The Barrington Research Healthcare Conference at the Hyatt Regency
Hotel in Chicago on Tuesday, August 25, 2009. The format for this
conference does not include formal presentations.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing,
manufacturing and selling innovative cardiac surgical ablation systems
designed to create precise lesions, or scars, in cardiac, or heart,
tissue. Medical journals have described the adoption by leading
cardiothoracic surgeons of the AtriCure Isolator® bipolar
ablation system as a treatment alternative during open-heart surgical
procedures to create lesions in cardiac tissue to block the abnormal
electrical impulses that cause atrial fibrillation, or AF, a rapid,
irregular quivering of the upper chambers of the heart. Additionally,
medical journals and leading cardiothoracic surgeons have described the
AtriCure Isolator system as a promising treatment alternative
for patients who may be candidates for sole-therapy minimally invasive
procedures. AF affects more than 5.5 million people worldwide and
predisposes them to a five-fold increased risk of stroke. The FDA has
cleared the AtriCure Isolator system and AtriCure’s multifunctional pen
and CoolrailTM linear ablation device, for the ablation, or
destruction, of cardiac tissue during surgical procedures. Additionally,
the FDA has cleared AtriCure’s multifunctional pen for temporary pacing,
sensing, stimulating and recording during the evaluation of cardiac
arrhythmias and AtriCure’s Cryo1 system for the cryosurgical treatment
of cardiac arrhythmias. To date, the FDA has not cleared or approved
AtriCure’s products for the treatment of AF.
AtriCure, Inc.
Julie A. Piton, 513-755-4561
Vice President and
Chief Financial Officer
jpiton@atricure.com
